Oragenics (OGEN) Competitors $1.26 -0.01 (-0.39%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGEN vs. NRSN, BLRX, SYBX, TLPH, THAR, IBIO, LSB, EDSA, MTVA, and CARMShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include NeuroSense Therapeutics (NRSN), BioLineRx (BLRX), Synlogic (SYBX), Talphera (TLPH), Tharimmune (THAR), iBio (IBIO), LakeShore Biopharma (LSB), Edesa Biotech (EDSA), MetaVia (MTVA), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. Its Competitors NeuroSense Therapeutics BioLineRx Synlogic Talphera Tharimmune iBio LakeShore Biopharma Edesa Biotech MetaVia Carisma Therapeutics Oragenics (NYSE:OGEN) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Which has more volatility and risk, OGEN or NRSN? Oragenics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Does the media prefer OGEN or NRSN? In the previous week, NeuroSense Therapeutics had 3 more articles in the media than Oragenics. MarketBeat recorded 4 mentions for NeuroSense Therapeutics and 1 mentions for Oragenics. NeuroSense Therapeutics' average media sentiment score of 1.04 beat Oragenics' score of -1.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Oragenics Negative NeuroSense Therapeutics Positive Is OGEN or NRSN more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% NeuroSense Therapeutics N/A N/A -445.40% Do insiders and institutionals have more ownership in OGEN or NRSN? 18.7% of Oragenics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 4.9% of Oragenics shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, OGEN or NRSN? NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenicsN/AN/A-$20.66M-$21.42-0.06NeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-2.13 Do analysts prefer OGEN or NRSN? NeuroSense Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 1,117.39%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Oragenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryNeuroSense Therapeutics beats Oragenics on 12 of the 14 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.22M$836.44M$5.72B$21.43BDividend YieldN/A4.84%5.72%3.50%P/E Ratio-0.181.1875.1429.79Price / SalesN/A26.49513.5568.87Price / CashN/A19.5625.8118.13Price / Book2.076.6413.534.64Net Income-$20.66M-$4.13M$3.28B$999.44M7 Day Performance8.58%0.84%0.01%0.96%1 Month Performance10.00%6.08%4.45%4.39%1 Year Performance-91.48%25.57%76.84%14.04% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenics0.1045 of 5 stars$1.27-0.4%N/A-92.0%$5.22MN/A-0.185Short Interest ↑NRSNNeuroSense Therapeutics2.5786 of 5 stars$1.36+16.2%$14.00+929.4%-14.1%$18.59MN/A-2.5210High Trading VolumeBLRXBioLineRx3.331 of 5 stars$4.24+16.2%$26.00+513.2%-84.9%$18.06M$28.94M-0.4840Positive NewsGap UpSYBXSynlogic1.6482 of 5 stars$1.50+2.7%N/A+17.5%$17.55M$10K-18.7580Positive NewsShort Interest ↓Gap UpTLPHTalphera2.0152 of 5 stars$0.85-0.4%$5.00+488.2%+8.9%$17.44M$650K-2.1219Gap DownTHARTharimmune2.4691 of 5 stars$3.05+9.3%$17.00+457.4%-1.0%$17.35MN/A-0.502Positive NewsIBIOiBio1.6872 of 5 stars$0.88+6.0%$5.00+466.4%-53.6%$17.35M$375K-0.51100Short Interest ↑LSBLakeShore Biopharma1.2391 of 5 stars$0.83-0.4%N/A-86.6%$17.32M$614.96M0.00773Short Interest ↓EDSAEdesa Biotech1.4516 of 5 stars$2.45+0.9%$5.00+104.0%-43.6%$17.25MN/A-1.8620Gap UpMTVAMetaVia2.3779 of 5 stars$0.68+0.1%$7.50+1,004.9%N/A$16.43MN/A0.008CARMCarisma Therapeutics2.6294 of 5 stars$0.39-5.4%$1.93+391.6%-66.1%$16.36M$10.77M-0.2520News CoverageShort Interest ↑ Related Companies and Tools Related Companies NeuroSense Therapeutics Competitors BioLineRx Competitors Synlogic Competitors Talphera Competitors Tharimmune Competitors iBio Competitors LakeShore Biopharma Competitors Edesa Biotech Competitors MetaVia Competitors Carisma Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | SponsoredAmerica’s most terrifying chart?MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
